Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02788981 · ClinicalTrials.gov registry record · Phase 2

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by University of Chicago.

Active
Registry status
Phase 2
Development phase
29
Enrollment target
5
Study locations

NCT02788981 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by University of Chicago. The registered enrollment target is 29 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02788981, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by University of Chicago.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
29 participants
Enrollment target
5
Study locations

Study Summary

This is a randomized, placebo-controlled, double-blind, phase II trial of nab-paclitaxel with or without mifepristone for advanced, glucocorticoid receptor-positive, triple-negative breast cancer. A total of 64 patients will receive nab-paclitaxel. Patients will be randomly assigned to either receive placebo or to receive mifepristone daily on the day prior to and day of each dose of nab-paclitaxel. Patients will be enrolled over 12 months and followed for 12 months following completion of study. To expand and follow up on the investigators understanding of a potential pharmacokinetic (PK) interaction between nab-paclitaxel and mifepristone, investigators will perform PK studies in the first 20 patients enrolled at pre-specified "PK sites".

Conditions Studied

Breast Cancer

Interventions

  • OTHER Placebo
  • DRUG Nab-Paclitaxel
  • DRUG Mifepristone

Study Locations (5)

Illinois

  • University of Chicago - Chicago
  • Northshore University HealthSystem - Evanston

Alabama

  • University of Alabama - Birmingham - Birmingham

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Wisconsin

  • Froedtert and the Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2017-03-28
Est. Completion 2026-08
Phase Phase 2

Sponsor

University of Chicago

796 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02788981

The ClinicalTrials.gov registry entry for NCT02788981 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02788981 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Illinois, Alabama, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02788981 about?

NCT02788981 is a clinical study titled "Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer". This is a randomized, placebo-controlled, double-blind, phase II trial of nab-paclitaxel with or without mifepristone for advanced, glucocorticoid receptor-positive, triple-negative breast cancer. A total of 64 patients will receive nab-paclitaxel. Patients will be randomly assigned to either receiv...

What is the current status of trial NCT02788981?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2017-03-28. Estimated completion is 2026-08.

What conditions does trial NCT02788981 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT02788981?

The interventions under investigation include: Placebo (OTHER), Nab-Paclitaxel (DRUG), Mifepristone (DRUG).

Who is sponsoring clinical trial NCT02788981?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02788981 being conducted?

This trial has 5 study locations across Alabama, Illinois, Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.